drug
apixaban ODT
Marketedupdated 5mo agoby Bristol-Myers Squibb Co
Approvedannual revenue · 2024–2024peak $13.3B
community read0 votes
🐶 often sniffed alongside
top 8- drugapixaban5 co-mentions · 2 sources
- drugapixaban ER5 co-mentions · 2 sources
- tagOncology2 co-mentions · 1 sources
- tagHematology2 co-mentions · 1 sources
- tagAdCom2 co-mentions · 1 sources
- tag510(k) Clearance2 co-mentions · 1 sources
- tagDiagnostics Company2 co-mentions · 1 sources
- companyMedical University of Gdansk1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 14 investigational indications.
all catalysts(1)
Trials studying apixaban ODT
- phase3REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
- phase3Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
- phase1Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant
- N/ADEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
- phase2Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
- phase3Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
- phase3A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- phase1A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 21, 2026
43 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (16)
- May 22, 2041patentUS 11896586*PED
- Nov 22, 2040formulationUS 11896586
- Aug 24, 2031patentUS 9326945*PED4.9y
- Aug 24, 2031patentUS 9326945*PED4.9y
- Aug 24, 2031patentUS 9326945*PED4.9y
- Feb 24, 2031formulationUS 93269454.4y
- Feb 24, 2031formulationUS 93269454.4y
- Feb 24, 2031formulationUS 93269454.4y
- May 21, 2027patentUS 6967208*PED224d
- May 21, 2027patentUS 6967208*PED224d
- May 21, 2027patentUS 6967208*PED224d
- May 21, 2027patentUS 6967208*PED224d
- Nov 21, 2026compositionUS 696720843d
- Nov 21, 2026compositionUS 696720843d
- Nov 21, 2026compositionUS 696720843d
- Nov 21, 2026compositionUS 696720843d
FDA exclusivities (8)
- Oct 17, 2028PEDPediatric (6mo bonus)2.0y
- Oct 17, 2028PEDPediatric (6mo bonus)2.0y
- Oct 17, 2028PEDPediatric (6mo bonus)2.0y
- Oct 17, 2028PEDPediatric (6mo bonus)2.0y
- Apr 17, 2028NPPNew Product (3y)1.5y
- Apr 17, 2028NPPNew Product (3y)1.5y
- Apr 17, 2028NSNS1.5y
- Apr 17, 2028NPNP1.5y
News(10)
- Q3 layoffs down YOY, with 90% fewer biopharma employees affectedBig Pharma companies including Bristol Myers Squibb, Johnson & Johnson and Novartis are among those that made or planned layoffs in Q3. Those cuts could affect over 1,800 employees, with New Jersey…biospace · 17h ago
- Significant stock movers of September: Viking soars, Longeveron slidesViking Therapeutics rode strong obesity data before a major capital raise, while Longeveron’s mid-stage setback prompted questions about its future.biospace · 3d ago
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 6d ago
- Bristol Myers trial revisions shake confidence in new class of fibrosis drugsA spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the…biopharma_dive · 8d ago
- August biopharma layoffs impact just over 500, down 90% year over yearLast month, biotech and pharma companies making or planning workforce cuts included three whose reductions will more than halve their workforces. Blueprint Medicines’ layoffs will affect the most e…biospace · 28d ago
- Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsBMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.biospace · 1mo ago
- BMS picks Texas for new $2.3B manufacturing campusBristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.biospace · 1mo ago
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 2mo ago
- No deal between AstraZeneca and BMS, senior source insists: ReutersReuters has deflated rumors that AstraZeneca and Bristol Myers Squibb are discussing a possible merger, letting the air out of industry-wide speculation over what could have been the largest deal i…biospace · 2mo ago
- Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcommsThe industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second qu…biospace · 2mo ago
Data sources
last refreshed 49m ago
Found something off?
comments(0)
5-min edit window · permanent after that